Adicet Bio Inc expects its $158.5 million in cash, cash equivalents, and short-term investments as of December 31, 2025, to fund operations for at least the next twelve months, with plans to meet with the FDA in Q2 2026 for prula-cel pivotal trial design.
Bullish
Adicet Bio Inc leverages a novel "off-the-shelf" gamma delta T cell platform, with lead candidate prula-cel showing clinical progress and Fast Track designation, alongside strategic prioritization of ADI-212 for mCRPC.
Bearish
Adicet Bio Inc faces significant risks from high dependence on prula-cel's regulatory approval, potential manufacturing delays due to third-party reliance, and challenges in protecting intellectual property against better-resourced competitors.